Former senior vice president of quality, Dr. Wenfang Miao, has been appointed as PharmaBlock’s chief executive officer.
 
In this new role, Miao will lead and drive the implementation of the company’s strategy, continue building a world-class team and manage global operation of the company to meet and exceed customer’s demand.
 
Miao joined PharmaBlock as senior vice president of quality in 2020, responsible for leading the team to further improve the quality system and deliver high-quality services and products to our clients worldwide.
 
Miao is a seasoned pharmaceutical executive with over 20 years of experience in pharmaceutical R&D, quality control, quality assurance, and CMC (Chemistry, Manufacturing and Control) regulatory affairs. Prior to joining PharmaBlock, Miao served as senior vice president of quality and regulatory affairs at Pharmaron and vice president at WuXi STA Pharmaceuticals. Miao also worked in CMC development at GSK and Elan Pharmaceuticals in the US.
 
“Since joining PharmaBlock, Dr. Miao has made enormous contributions to the enhancement of the quality system and establishment of our fully integrated CMC service platform,” said Dr. Minmin Yang, chairman of PharmaBlock. “We believe that as the new CEO and with such rich management experience, in-depth insight to business growth, and the leadership vision to the pharmaceutical field, Dr. Miao will lead PharmaBlock to the next new phase. Our team will continue high-quality and efficient support to our partners in advancing their drug discovery and development programs and deliver groundbreaking treatment to those in need.”